Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MK-767
- Development stage
- Discontinued
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
MK-767 (also known as KRP-297) is a small molecule dual agonist of the peroxisome proliferator-activated receptors alpha (PPARα) and gamma (PPARγ). It was developed through a collaboration between Kyorin Pharmaceutical, Banyu Pharmaceutical, and Merck & Co. for the treatment of type 2 diabetes and associated dyslipidemia. By targeting both PPAR isoforms, the drug aimed to improve insulin sensitivity (via PPARγ) while simultaneously addressing lipid profiles (via PPARα). However, development was discontinued in Phase III clinical trials in 2004 due to safety concerns, specifically findings of rare tumors in long-term rodent carcinogenicity studies.
- Other names
- Y180U02GSBY-180U02GSBY 180U02GSB934017-32-0
02
Targets
PPARA (Peroxisome proliferator-activated receptor alpha)PPARG (Peroxisome proliferator-activated receptor gamma)
Beyond the preview
Go deeper on MK-767.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MK-767.